Shares of Regeneron Pharmaceuticals Inc. slipped 3.63% to $527.78 Friday, on what proved to be an all-around poor trading ...

The new plans are in addition to $21B that the drug manufacturer has already committed to U.S. research, development and ...

We recently compiled a list of the 10 Jim Cramer Stocks with Huge Upside Potential. In this article, we are going to take a ...

Regeneron Pharmaceuticals Inc. closed 54.78% below its 52-week high of $1,211.20, which the company reached on August 27th.

On track to complete enrollment of the global Phase 3 HAELO study in hereditary angioedema (HAE) in the third quarter of 2025Dosed first patient in the global Phase 3 MAGNITUDE-2 study evaluating nexi ...

Four Gatton Academy of Mathematics and Science students presented their research at the Louisville Regional Science and ...

We recently published a list of Billionaire Mario Gabelli’s 10 Large-Cap Stock Picks with Huge Upside Potential. In this ...

This was the stock's second consecutive day of losses.

Learn more about whether Alnylam Pharmaceuticals, Inc. or Exact Sciences Corporation is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Schonfeld Strategic Advisors made a bold biotech play by boosting its Regeneron holdings by over 475% in Q4. The firm added ...

We recently published an article titled Jim Cramer Listed 20 Best Performing Stocks of the Last 20 Years. In this article, we ...

Robert Radick writes his first health care enforcement roundup column for the NYLJ. "This new column will, every two months, ...